Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) will be releasing its earnings data after the market closes on Monday, November 4th. Analysts expect Aquestive Therapeutics to post earnings of ($0.12) per share for the quarter. Aquestive Therapeutics has set its FY 2024 guidance at EPS.Investors interested in participating in the company's conference call can do so using this link.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.08. The business had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the previous year, the company earned ($0.10) earnings per share. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Aquestive Therapeutics Price Performance
Shares of NASDAQ:AQST remained flat at $5.49 during trading hours on Monday. 1,821,417 shares of the stock traded hands, compared to its average volume of 1,751,093. The company's 50 day moving average is $4.77 and its two-hundred day moving average is $3.76. The firm has a market capitalization of $499.80 million, a P/E ratio of -12.98 and a beta of 2.85. Aquestive Therapeutics has a twelve month low of $1.41 and a twelve month high of $6.23.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on AQST. Leerink Partners upped their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an "outperform" rating in a research note on Friday. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $8.83.
View Our Latest Analysis on AQST
About Aquestive Therapeutics
(
Get Free Report)
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
Further Reading
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
